semaglutide sweden Oral Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients Semaglutide Shows Surprising Mental Health

Although safety data could not be pooled due to lack of events, no differences were observed in the risk of severe hypoglycaemia, diabetic ketoacidosis, genitourinary infections and gastrointestinal side effects

In 'Bedside to Bench,' Rachel Larder and Stephen O'Rahilly peruse a human study with dieters who regained weight despite a successful diet

Semaglutide is a GLP-1 analogue under investigation regarding complex effects on glucose metabolism, appetite, and energy expenditure

The wild card-to-uncertainty about GLP-1 meds growth will be reimbursement: spending will continue to accelerate with upside if more widely reimbursed, IQVIA projects

Microdosing GLP-1 agonistsusing doses below FDA-approved levels for T2D or obesityis rapidly gaining traction as an off-label strategy to improve tolerability, tailor titration, and manage costs